Comparison of Epirubicin and Doxorubicin Cardiotoxicity in Children and Adolescents Treated Within the German Cooperative Soft Tissue Sarcoma Study (CWS)

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2005 Oct 6

PMID 16205946

Citations 5

Authors

W Stohr

M Paulides

I Brecht

A Kremers

J Treuner

T Langer

J D Beck

Affiliations

Soon will be listed here.

Abstract

Purpose: Up to now, cardiotoxicity of epirubicin has been studied almost exclusively in adult cancer patients. The aim of this study was to investigate epirubicin in children and adolescents, in comparison with doxorubicin.

Methods: About 172 soft tissue sarcoma patients (mean age at diagnosis: 8.3 years), treated with epirubicin (median cumulative dose: 450 mg/m2) or doxorubicin (median cumulative dose: 240 mg/m2) within the high-risk group of the CWS-96 study, were examined in a prospective multicentre study. Heart function was analysed by echocardiography, measuring left-ventricular fractional shortening (FS). The median follow up was 27.7 months.

Results: Incidence of clinically manifest cardiomyopathy was 0% (0/60; 95% CI: 0-6.0%) in patients treated with epirubicin, and 0.9% (1/108; 95% CI: 0-5.1%) in patients treated with doxorubicin. A further three patients showed subclinical cardiomyopathy. There was no difference in FS between the two treatment arms.

Conclusions: Cardiotoxicity was low in our study. For the short term, cardiotoxicity seems to be only a minor problem in patients treated with epirubicin as applied in this cohort.

Citing Articles

Acute and early-onset cardiotoxicity in children and adolescents with cancer: a systematic review.

Kouwenberg T, van Dalen E, Feijen E, Netea S, Bolier M, Slieker M BMC Cancer. 2023; 23(1):866.

PMID: 37710224 PMC: 10500898. DOI: 10.1186/s12885-023-11353-9.

Metformin Alleviates Epirubicin-Induced Endothelial Impairment by Restoring Mitochondrial Homeostasis.

Sun Q, Jia H, Cheng S, Wang Y, Wang J Int J Mol Sci. 2023; 24(1).

PMID: 36613786 PMC: 9820471. DOI: 10.3390/ijms24010343.

Cardiac tolerability of concurrent administration of trastuzumab and anthracycline-based regimen as adjuvant chemotherapy for breast cancer.

Watanabe N, Otsuka S, Sasaki Y, Shimojima R, Wani Y, Uchino K Breast Care (Basel). 2014; 9(1):46-51.

PMID: 24803887 PMC: 3995382. DOI: 10.1159/000358754.

Can anthracycline therapy for pediatric malignancies be less cardiotoxic?.

Fulbright J, Huh W, Anderson P, Chandra J Curr Oncol Rep. 2010; 12(6):411-9.

PMID: 20820959 DOI: 10.1007/s11912-010-0129-9.

Different anthracycline derivates for reducing cardiotoxicity in cancer patients.

van Dalen E, Michiels E, Caron H, Kremer L Cochrane Database Syst Rev. 2010; (5):CD005006.

PMID: 20464735 PMC: 6457588. DOI: 10.1002/14651858.CD005006.pub4.

References

Sorensen K, Levitt G, Bull C, Chessells J, Sullivan I . Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity. J Clin Oncol. 1997; 15(1):61-8. DOI: 10.1200/JCO.1997.15.1.61. View

Bossi G, Lanzarini L, Laudisa M, Klersy C, Raisaro A, Arico M . Echocardiographic evaluation of patients cured of childhood cancer: a single center study of 117 subjects who received anthracyclines. Med Pediatr Oncol. 2001; 36(6):593-600. DOI: 10.1002/mpo.1135. View

Kapusta L, Thijssen J, Antonius T, Mulder J, Daniels O . Tissue Doppler imaging in detection of myocardial dysfunction in survivors of childhood cancer treated with anthracyclines. Ultrasound Med Biol. 2000; 26(7):1099-108. DOI: 10.1016/s0301-5629(00)00252-0. View

Sorensen K, Levitt G, Sebag-Montefiore D, Bull C, Sullivan I . Cardiac function in Wilms' tumor survivors. J Clin Oncol. 1995; 13(7):1546-56. DOI: 10.1200/JCO.1995.13.7.1546. View

Steinherz L, Graham T, HURWITZ R, Sondheimer H, Schwartz R, Shaffer E . Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group. Pediatrics. 1992; 89(5 Pt 1):942-9. View

Torti F, Bristow M, Lum B, Carter S, HOWES A, Aston D . Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res. 1986; 46(7):3722-7. View

Meinardi M, van Veldhuisen D, Gietema J, Dolsma W, Boomsma F, van den Berg M . Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol. 2001; 19(10):2746-53. DOI: 10.1200/JCO.2001.19.10.2746. View

Cottin Y, Touzery C, Dalloz F, Coudert B, Toubeau M, Riedinger A . Comparison of epirubicin and doxorubicin cardiotoxicity induced by low doses: evolution of the diastolic and systolic parameters studied by radionuclide angiography. Clin Cardiol. 1998; 21(9):665-70. PMC: 6655270. DOI: 10.1002/clc.4960210911. View

Langer T, Stohr W, Paulides M, Kremers A, Dorr H, Gobel U . Prospective multicenter registration of major late sequelae in sarcoma patients using the Late Effects Surveillance System (LESS). Klin Padiatr. 2005; 217(3):176-81. DOI: 10.1055/s-2005-836503. View

10.

McKillop J, Bristow M, Goris M, Billingham M, Bockemuehl K . Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. Am Heart J. 1983; 106(5 Pt 1):1048-56. DOI: 10.1016/0002-8703(83)90651-8. View

11.

Alderton P, Gross J, Green M . Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model. Cancer Res. 1992; 52(1):194-201. View

12.

Green D, Grigoriev Y, Nan B, Takashima J, Norkool P, DAngio G . Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study group. J Clin Oncol. 2001; 19(7):1926-34. DOI: 10.1200/JCO.2001.19.7.1926. View

13.

Jain K, Casper E, Geller N, Hakes T, Kaufman R, Currie V . A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol. 1985; 3(6):818-26. DOI: 10.1200/JCO.1985.3.6.818. View

14.

Kremer L, van Dalen E, Offringa M, VOUTE P . Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. Ann Oncol. 2002; 13(4):503-12. DOI: 10.1093/annonc/mdf118. View

15.

Lanzarini L, Bossi G, Laudisa M, Klersy C, Arico M . Lack of clinically significant cardiac dysfunction during intermediate dobutamine doses in long-term childhood cancer survivors exposed to anthracyclines. Am Heart J. 2000; 140(2):315-23. DOI: 10.1067/mhj.2000.108237. View

16.

Marx M, Langer T, Graf N, Hausdorf G, Stohr W, Ludwig R . Multicentre analysis of anthracycline-induced cardiotoxicity in children following treatment according to the nephroblastoma studies SIOP No.9/GPOH and SIOP 93-01/GPOH. Med Pediatr Oncol. 2002; 39(1):18-24. DOI: 10.1002/mpo.10081. View

17.

Steinherz L, Steinherz P, Tan C, Heller G, Murphy M . Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991; 266(12):1672-7. View

18.

Kremer L, van Dalen E, Offringa M, Ottenkamp J, VOUTE P . Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol. 2001; 19(1):191-6. DOI: 10.1200/JCO.2001.19.1.191. View

19.

Nielsen D, Jensen J, Dombernowsky P, Munck O, Fogh J, Brynjolf I . Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer. J Clin Oncol. 1990; 8(11):1806-10. DOI: 10.1200/JCO.1990.8.11.1806. View

20.

Lipshultz S, Colan S, Gelber R, Perez-Atayde A, Sallan S, Sanders S . Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991; 324(12):808-15. DOI: 10.1056/NEJM199103213241205. View